Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7112cd21c552f542e0dfabedc2116c8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-78 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12M3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 |
filingDate |
2006-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9911101fdeb524cad91e0824b9f15b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33fb8461a5b254f65991b590ace6e51a |
publicationDate |
2012-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
NZ-567286-A |
titleOfInvention |
Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
abstract |
Provided is a method for determining the efficacy of an anti-TNFa antibody, or an antigen-binding portion thereof, for treating a subject having ankylosing spondylitis (AS), said method comprising determining a post-treatment level of a collagen degradation biomarker and a post-treatment level of a synovitis biomarker in a sample(s) obtained from the subject, wherein a lower post-treatment level of the collagen degradation biomarker in the sample(s) relative to a known standard level of the collagen degradation biomarker associated with AS and a lower post-treatment level of the synovitis biomarker in the sample(s) relative to a known standard level or pre-treatment level of the synovitis biomarker associated with AS indicates that anti-TNFa antibody, or an antigen-binding portion thereof, is efficacious for treating the subject having AS. |
priorityDate |
2005-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |